triazoles has been researched along with Atherogenesis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 14 (93.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, A; Chen, Z; Das, S; Ganguly, R; Jia, Y; Lanting, L; Leung, A; Mandi, V; Natarajan, R; Reddy, MA; Schones, DE; Senapati, P; Wu, X; Zhang, S | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E | 1 |
| Dai, D; Dai, Y; Ding, Z; Mehta, JL; Wang, X | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
| Guan, M; He, F; Li, C; Li, J; Wang, L; Xu, W; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Jang, SW; Kim, J; Ko, J; Oh, M; Park, E; Park, S | 1 |
| Bando, YK; Ishizu, T; Kodama, K; Murohara, T; Node, K; Oyama, J; Sato, Y | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Bair, S; Bradner, JE; Brown, JD; Croce, K; Duan, Q; Federation, A; Griffin, G; Kung, A; Lichtman, A; Lin, CY; Luscinskas, FW; Newton, G; Paranal, RM; Plutzky, J; Wang, H; Yang, T | 1 |
| Clerici, M; Cossu, M; Masetti, M; Piconi, S; Pocaterra, D; Rainone, V; Rizzardini, G; Trabattoni, D | 1 |
| Belcher, JD; Geng, JG; Huo, Y; Slungaard, A; Tang, R; Viollet, B; Wang, H; Wang, J; Wu, C; Zhang, C; Zhang, W; Zhu, C | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Ikeda, T; Kirinoki-Ichikawa, S; Kubota, Y; Miyamoto, M; Mizuno, K; Takagi, G; Tanaka, K | 1 |
| Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR | 1 |
| Peng, K; Tang, YL; Wang, S; Xu, ZX; Yang, YZ | 1 |
1 review(s) available for triazoles and Atherogenesis
| Article | Year |
|---|---|
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
4 trial(s) available for triazoles and Atherogenesis
| Article | Year |
|---|---|
Rationale and design of a study to evaluate the effects of sitagliptin on atherosclerosis in patients with diabetes mellitus: PROLOGUE study.
Topics: Adult; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Humans; Prospective Studies; Pyrazines; Research Design; Sitagliptin Phosphate; Triazoles | 2014 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Nitroglycerin; Prospective Studies; Pyrazines; Regression Analysis; Sitagliptin Phosphate; Triazoles; Vasodilation; Vasodilator Agents | 2012 |
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin | 2013 |
10 other study(ies) available for triazoles and Atherogenesis
| Article | Year |
|---|---|
Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Aorta; Atherosclerosis; Azepines; Cells, Cultured; Gene Expression Regulation; Histones; Hypertension; Male; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Sprague-Dawley; RNA, Long Noncoding; Signal Transduction; Triazoles | 2017 |
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
Topics: Animals; Anti-Retroviral Agents; Apolipoproteins E; Atherosclerosis; CCR5 Receptor Antagonists; Cell Movement; Chemokine CCL2; Chemokine CCL5; Cyclohexanes; Disease Models, Animal; Intercellular Adhesion Molecule-1; Interleukin-17; Macrophages; Male; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Ritonavir; Treatment Outcome; Triazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2013 |
DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway.
Topics: Atherosclerosis; Cell Line; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Foam Cells; Humans; Lipoproteins, LDL; Macrophages; Protein Kinase C; Pyrazines; Receptors, Scavenger; Sitagliptin Phosphate; Triazoles | 2014 |
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pyrazines; Random Allocation; Sitagliptin Phosphate; Triazoles | 2014 |
The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Benzoquinones; Cell Cycle Checkpoints; Cell Line; Cell Movement; Cell Proliferation; Cholesterol; Diet, High-Fat; Gene Expression Regulation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Plaque, Atherosclerotic; Primary Cell Culture; Receptors, LDL; Signal Transduction; Triazoles | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.
Topics: Acetylation; Animals; Atherosclerosis; Azepines; Cell Adhesion; Cell Movement; Cells, Cultured; Chromatin; E-Selectin; Endothelial Cells; Endothelium, Vascular; Enhancer Elements, Genetic; Histones; Humans; Inflammation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B p50 Subunit; Nuclear Proteins; Protein Binding; Regulatory Sequences, Nucleic Acid; RNA Polymerase II; Signal Transduction; SOXF Transcription Factors; Transcription Factor RelA; Transcription Factors; Transcription Initiation, Genetic; Transcription, Genetic; Triazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2014 |
Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients.
Topics: Atherosclerosis; Carotid Intima-Media Thickness; Case-Control Studies; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Risk Factors; Treatment Outcome; Triazoles; Vascular Stiffness | 2016 |
Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway.
Topics: Adenosine A2 Receptor Antagonists; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Blood Coagulation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Fibrinolytic Agents; Humans; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A; Ribonucleosides; RNA, Messenger; Sepsis; Signal Transduction; Thromboplastin; Transcription Factor AP-1; Triazines; Triazoles; Up-Regulation; Venous Thrombosis | 2010 |
Opposite effects of WEB2086 on angiogenesis in atheromas and ischemic hindlimb of apoE gene deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azepines; Capillaries; Cholesterol; Hindlimb; Ischemia; Lipoproteins, LDL; Male; Mice; Neovascularization, Physiologic; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Triazoles | 2007 |